user

Dabigatran and rivaroxaban have different risk factors for bleeding in atrial fibrillation patients

被引：0
|
作者：
Nishino, M. [1 ]
Okamoto, N. [1 ]
Tanaka, A. [1 ]
Mori, N. [1 ]
Yoshimura, T. [1 ]
Makino, N. [1 ]
Egami, Y. [1 ]
Shutta, R. [1 ]
Tanouchi, J. [1 ]
机构：
[1] Osaka Rosai Hosp, Sakai, Osaka 5918025, Japan
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6201
引用
收藏
页码：1080 / 1080
页数：1
相关论文
共 50 条
  • [41] Direct Comparisons of Apixaban, Dabigatran and Rivaroxaban in Atrial Fibrillation
    Jansson, Martin U.
    Sjogren, Vilhelm
    Sjalander, Sara
    Renlund, Henrik
    Norrving, Bo
    Sjalander, Anders
    CIRCULATION, 2018, 138
  • [42] GASTROINTESTINAL BLEEDING PROPHYLAXIS IN ATRIAL FIBRILLATION PATIENTS RECEIVING DABIGATRAN
    Nantsupawat, T.
    Soontrapa, S.
    Nantsupawat, N.
    Klomjit, S.
    Tantrachoti, P.
    Sotello, D.
    Mazek, H.
    Perez-Verdia, A. P.
    CARDIOLOGY, 2016, 134 : 228 - 228
  • [43] Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population
    Amin, A.
    Keshishian, A.
    Trocio, J.
    Dina, O.
    Le, H.
    Rosenblatt, L.
    Mardekian, J.
    Zhang, Q.
    Baser, O.
    Liu, X.
    Vo, L.
    EUROPEAN HEART JOURNAL, 2017, 38 : 964 - 964
  • [44] Combination of Rivaroxaban and Amiodarone Increases Bleeding in Patients With Atrial Fibrillation
    Wang, Zi
    Li, Xiaoyu
    Zou, Ye
    Li, Xiaoye
    Lv, Qianzhou
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 761 - 770
  • [45] Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation
    Semeraro, Fabrizio
    Incampo, Francesca
    Ammollo, Concetta T.
    Dellanoce, Claudia
    Paoletti, Oriana
    Testa, Sophie
    Colucci, Mario
    THROMBOSIS RESEARCH, 2016, 138 : 22 - 29
  • [46] Prescription of dabigatran and rivaroxaban at discharge for atrial fibrillation patients with different classes of renal function: Findings from the CCC-atrial fibrillation project
    Yang, Na
    Liu, Jing
    Liu, Jun
    Hao, Yongchen
    Smith, Sidney C., Jr.
    Huo, Yong
    Fonarow, Gregg C.
    Ge, Junbo
    Taubert, Kathryn A.
    Morgan, Louise
    Han, Yaling
    Ma, Changsheng
    Zhao, Dong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (16) : C137 - C137
  • [47] Real-World Risk of Thromboembolism or Bleeding with Warfarin or Dabigatran Therapy in Patients with Atrial Fibrillation
    Charland, Scott I.
    Malone, Daniel C.
    Agatep, Barnabie C.
    Herrera, Vivian
    Hawk, Gosia S.
    Schrader, Bruce J.
    Stanek, Eric J.
    CIRCULATION, 2012, 126 (21)
  • [48] Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation
    Lee, Ki Hong
    Park, Hyung Wook
    Lee, Nuri
    Hyun, Dae Young
    Won, Jumin
    Oh, Sung Sik
    Park, Hyuk Jin
    Kim, Yongcheol
    Cho, Jae Yeong
    Kim, Min Chul
    Sim, Doo Sun
    Yoon, Hyun Joo
    Yoon, Nam Sik
    Kim, Kye Hun
    Hong, Young Joon
    Kim, Ju Han
    Ahn, Youngkeun
    Jeong, Myung Ho
    Park, Jong Chun
    Cho, Jeong Gwan
    EUROPACE, 2017, 19 : 1 - 9
  • [49] Predictive value of four score systems on the bleeding risk in atrial fibrillation patients treated with dabigatran
    丁聪聪
    China Medical Abstracts (Internal Medicine), 2020, 37 (04) : 210 - 211
  • [50] Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data
    Hernandez, Inmaculada
    Zhang, Yuting
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (01) : 37 - 47
12345